The changes in the European pharmacovigilance legislation that took effect in 2012 allowed patients and consumers to report adverse drug reactions (ADRs) directly to the competent national authorities. The adverse reaction reports from patients no longer need to be confi rmed by a healthcare professional before being sent to the regulatory authorities. The implementation of these legal changes poses a challenge to all participants in the pharmacovigilance system. In order to be able to actively report ADRs, patients need to have a convenient framework and conditions. Moreover, algorithms and standards for accepting, processing, validating and further analysis of the reports must be developed and established in practice. Adverse reaction reports from patients and consumers have different characteristics from those sent by healthcare professionals. Due to the lack of professional fi lter, the majority of the cases provide predominantly subjective information but they also give insight as to how the adverse reaction might affect everyday life. This could be described by the health-related quality-of-life instrument which is still not widely used in the assessment process. The patients' compliance, adherence and satisfaction with the therapy also have to be included in the investigation algorithm of any case study. 1, 2 Bulgaria is one of the fi rst countries to start monitoring the safety of medicines use with the creation of the national pharmacovigilance commission in 1974; it subsequently joined the WHO Programme for International Drug Monitoring in 1975. As part of the evolution of drug regulatory system in Europe, Bulgaria actively develops, improves and maintains the national drug surveillance system by receiving and analyzing safety data from healthcare professionals. In 2007, Bulgaria, while joining the EU, got directly involved in the drug regulation processes on European level and fully harmonized the national legislation in this respect. In 2012, the Bulgarian pharmacovigilance system accepted the changes in the pharmacovigilance legislation and the Bulgarian Drug Agency (BDA), the only national competent authority currently receives ADRs reports directly from patients as well as from healthcare professionals and marketing authorization holders (MAH).
AIM
The aim of the study was to analyze Bulgaria's representative database of ADR reports from patients in BDA received in the fi rst 5 years since the changes in the European and local pharmacovigilance legislation and to defi ne the specifi c characteristics and trends of patient reporting.
MATERIALS AND METHODS
We analyzed all cases (n=342) in the BDA database of patient ADRs reports received between June 2012 and December 2016. The in-depth analysis of the cases was based on the following criteria:
• Method of reporting;
• Serious/non-serious ADRs ratio;
• Expected/unexpected ADRs ratio;
• Most frequently reported pharmacological groups according to ATC code;
• Demographic characteristics of patients (age and sex).
RESULTS
The total number of the reports included in the analysis was rather small in comparison with that in similar studies published in the literature. This could be explained with lack of adequate knowledge on pharmacovigilance system, the insuffi cient level of health education, and positive attitude in patient/ consumers/reporters. 3 Another possible explanation could be the physicians' attitude towards direct patient reporting ADRs as 87% of them believe patient should report to physicians and only 24% -to the BDA. 4 During the last two years of the analyzed period, 2015 and 2016, a rather stable number of reports has been achieved -16 reports per 1 million inhabitants/year. Generally, the number of patient reports received in the BDA tends to grow, especially in 2014 when the number of consumer reports was 252% higher than that in the previous year ( Fig. 1) . 5 
METHOD OF REPORTING
The analysis identifi ed four ways of reporting ADR from patients:
• Via the marketing authorization holder;
• Via the web-based form on the website of the Bulgarian drug agency (www.bda.bg);
• Via e-mail directly to BDA ;
• Through the national phone line for reporting ADR included in the patient leafl et.
During the fi rst six months since the introduction of the new legislation (second half of 2012) the reports received in the BDA via the web-based form and those sent by the MAH were equal in number. This could be a sign of the low level of knowledge on pharmacovigilance system and recognition of BDA as the competent authority on medicinal products. Patients tend to contact the MAH rather than the executive state agency. The situation was the same in 2013 when the largest number of ADRs from patients was received via the MAHs. In 2014 the number of reports sent via the form on the BDA website showed a slight increase but it was still not comparable to the number of reports received via the MAHs.
Phone reporting was introduced at the beginning of 2015. The phone number is equally acces- sible to all patients as it is included in the patient information leafl et of all medicinal products. This clearly highlights the importance of reading the patient leafl et before and during therapy. In 2015, the numbers of ADR reports received by phone and indirectly through MAHs were approximately similar. The phone call was the most preferred way of reporting ADRs in comparison with the number of ADRs reported via the BDA website and e-mail. In 2016, the number of sent web-based reports was twice as big compared to that in 2015. However, the most numerous groups were the phone reports and the indirect ones. The smallest amount of ADRs was reported via e-mail (Fig. 2) . The results of a questionnaire study conducted amongst Bulgarian physicians showed that more than 57% of the participants declared their most preferred way of reporting ADRs to be an internet-based method followed by verbal reporting and a hard-copy form. 4 
SERIOUS/NON-SERIOUS ADRS RATIO
Only one patient report for serious ADR was received in 2012. In the following years, 2013, 2014, and 2015, consumers reported mostly serious ADRs. However, this does not correspond to physicians' opinion -they consider the ADRs experienced by patients to be non-serious in most of the cases. 4 In 2014 the amount of serious ADRs was four times bigger than that of the non-serious. This tendency changed for the fi rst time in 2016 when the reports for non-serious adverse reactions were more numerous. Nevertheless, there was still not a very great difference in their number. This aspect of consumer reporting in Bulgaria follows the characteristics of patient reporting worldwide ( Table 1) . A recent study conducted in the Netherlands showed that the quality of clinical information patients give when reporting adverse reactions is comparable to that provided by the healthcare professional reports. Both groups are willing to report a suspected ADR due to its severity which explains the bigger proportion of serious ADRs in the patient reports. 6 3. EXPECTED/UNEXPECTED ADRS RATIO As to the probability of occurrence of ADRs, that is, whether these ADRs are included in the summary of product characteristics (SPC) and in the patient leafl et over the study period, there is no clearly defi ned tendency. Most of the reported ADRs in 2012 and 2013 were unexpected. Generally, physicians consider the drug-reaction relationship to be either possible or probable. 4 In 2014, 2015 and 2016, reports concerned mostly known ADRs and during this three-year period the expected/unexpected ratio was quite stable. However, the analysis included cases which were diffi cult to assess in terms of whether the reported ADRs should be defi ned as expected or unexpected. Greater diffi culties arose in analyzing the information when it was reported by the patient. Therein lies one of the widely recognized disadvantages of patient reporting -transferring the information from lay language to international coding standards. Moreover, some of the terms used in the SPC are rather general and therefore could include a variety of conditions ( Table 1) . In Denmark, for example, patients tend to report adverse reactions related to psychiatric disorders, to disorders involving the nervous and reproductive systems, with a special emphasis on the emotional aspects of the reaction. A study from 2017 in the Netherlands showed that the number of spontaneous reports from patients concerning ADRs listed as important medical events is comparable to the sum of these reports by both healthcare professionals and MAHs. 2, 7 4. MOST FREQUENTLY REPORTED PHARMACOLOGICAL GROUPS ACCORDING TO ATC CODE In 2012, patient reports were equally spread across several pharmacological groups with ATC code J: anti-infectives for systemic use, ATC code C: cardiovascular system, and ATC code M: musculoskeletal system. In 2013, the biggest part of the reports concerned anti-infectives medicinal products followed by ATC code N: nervous system and code R: respiratory system. In 2013, one report concerned an adverse reaction related to homeopathic product. In 2014, the majority of the reports from patients concerned medicines with ATC code J as well as code L: antineoplastic and immunomodulating agents which includes new active substances used in the management of autoimmune pathology. In 2015, the tendency is still kept as again the greatest amount of reports concerned anti-infectives. The introduction of new anticoagulant agents in clinical practice can account for the presence of ATC code B: blood and blood forming organs in patient reports but also suspected adverse reactions related to use of medicines for respiratory, neurological and autoimmune diseases. In 2016, anti-infectives and immunomodulating agents were the most reported pharmacological classes as well as ATC code B.
During the whole period the number of ADRs related to neurological and cardiological medicines was relevantly constant. In 2016, the number of reports for ATC code G: genito urinary system and sex hormones was quite high (Fig. 3) .
DEMOGRAPHIC CHARACTERISTICS OF PATIENTS
Between 2013 and 2016, the patients who experienced ADRs were predominantly female. Male patients were more than female patients only in 2012. As to the age of patients taken from reports that include such information, the greatest number of patients were over 60 years old. The least active age group was between 15 and 30 years of age. A great part of the ADR reports concern patients in the age group of 1 to 15 years. This group included reports from parents or care-givers regarding their children and the reports of ADRs following vaccination (Fig. 4) .
DISCUSSION
The present study shows that there are a solid, but not very high number of adverse reaction reports sent by patients or consumers. Many authors have one of the most common motives for not reporting is the level of incertitude on which information is important, the analyzed data underlines the importance of the communication with healthcare professional to explain the mechanism of reporting. Along with the phone call patients also prefer reporting via the standardized web-based form which specifi es the information needed. 3 Despite the disadvantages of the spontaneous reporting system ADR reports from patients are a valuable source of information on safety of medicines. The analyzed data show that signifi cant number of the reactions reported from consumers commented that the insuffi cient level of reporting is probably the biggest disadvantage of the spontaneous reporting systems. Despite this known drawback, an analysis of the signals discussed at the 2012-2013 PRAC meetings shows that spontaneous reports have the biggest contribution in triggering safety signals (62%). Moreover, 60% of the discussed signals concern the safety of drugs that have been on the market more than 10 years. 8 This data once more confi rms the importance of spontaneous reporting system and the need of active post-marketing surveillance throughout the lifecycle of medicinal products.
We can conclude from the analysis of the database that as to the method of reporting patients preferred the phone call when reporting ADRs. As met the seriousness criteria. Moreover, the expectedness of the reported adverse events is diffi cult to evaluate and therefore many of the cases bring new knowledge on the benefi ts and risks of drug therapy. The high number of reports related to the use of medicines with ATC code J includes the post-vaccination reactions. Unfortunately, it could be explained also with the inappropriate use of antibiotics and over-the-counter sale in pharmacies. The conducted analysis shows that there is a complete lack of reports of ADRs related to homeopathic and herbal medicinal products. On the contrary, the Swedish Medical Products Agency has already used patient reports as a source of information for the evaluation of the safety concern of herbal medicinal product. 9 In Bulgaria, the food supple-Folia Medica I 2018 I Vol. 60 I No. 3 ments market is growing stable every year and their questionable safety is an emerging issue -in 2016 several reports were received suspecting side effects caused by food supplements intake. In Bulgaria, the competent authority on food supplements is the Bulgarian Food Safety Agency.
According to our data of consumer reports the typical patient who experiences ADR in the country has the following profi le: female, age 60-75 years and experiences adverse drug reactions related to the use of medicines ATC codes J, L or N.
CONCLUSION
The performed in-depth analysis of the centralized data-base of reported adverse drug reactions by patients shows that a rather stable level of patient reporting has been achieved in Bulgaria. There is a tendency of constant growth of the number of valid ADR reports every year. Phone call and web-based forms are the most preferred methods of reporting ADRs and communicating with the BDA which require developing a modern and accessible webbased platform for medicines related issues.
On the other hand, the serious/non-serious and expected/unexpected ADRs ratios show that Bulgaria is following the world tendencies for high level of reporting of unknown and insuffi ciently studied ADRs which meet the seriousness criteria. This is a solid proof of the benefi t patient reporting brings. The risk/benefi t assessment and the need of establishing a well-functioning high-quality system for receiving, validating and transmitting patient reports is clear. 10 The review of the most frequently reported pharmacological groups according to ATC codes could lead to the conclusion that the current pharmacovigilance methods are not sensitive enough for specifi c groups of medicines. The safety of vaccines, biological, herbal and homeopathic products need to be monitored more closely. 11, 12 
